Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $202.5 million.

  • Ultragenyx Pharmaceutical's Cash & Equivalents rose 34.45% to $202.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.5 million, marking a year-over-year increase of 34.45%. This contributed to the annual value of $173.7 million for FY2024, which is 18.66% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Cash & Equivalents of $202.5 million as of Q3 2025, which was up 14.86% from $176.3 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Cash & Equivalents peaked at $480.7 million during Q2 2024, and registered a low of $72.6 million during Q3 2023.
  • In the last 3 years, Ultragenyx Pharmaceutical's Cash & Equivalents had a median value of $150.6 million in 2024 and averaged $172.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 81.47% in 2023, then soared by 371.00% in 2024.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Cash & Equivalents stood at $307.6 million in 2021, then slumped by 56.78% to $132.9 million in 2022, then surged by 60.66% to $213.6 million in 2023, then declined by 18.66% to $173.7 million in 2024, then soared by 34.45% to $202.5 million in 2025.
  • Its Cash & Equivalents stands at $202.5 million for Q3 2025, versus $176.3 million for Q2 2025 and $127.1 million for Q1 2025.